Keyphrases
Acute Phase Proteins
16%
Adipose Tissue
100%
Adverse Effects
16%
C-reactive Protein
16%
Changes in Gene Expression
16%
Circulating Levels
16%
Days of Treatment
16%
Dexamethasone Treatment
100%
Energy Metabolism
16%
Gene Expression Profiling
16%
Glucose Intolerance
16%
Healthy Males
16%
Human Skeletal muscle
100%
Immune Signaling
16%
Inflammatory Pathways
16%
Inflammatory Response
16%
Insulin Sensitivity
16%
Longitudinal Treatments
16%
Metabolic
16%
Metabolic Tissues
16%
Mineralocorticoid Receptor
16%
Multiple Effects
100%
Number of Subjects
16%
Physiological Effects
16%
Prescription Drugs
16%
Primary Outcome Measure
16%
Response to Stress
16%
Sari
16%
Serum Amyloid A
16%
Single Time Point
16%
Skeletal muscle
33%
Skeletal muscle Tissue
100%
Specific Features
16%
Stress-responsive Genes
16%
Tissue Remodeling
33%
Urinary Cortisol
16%
Valles
16%
INIS
adipose tissue
100%
biochemistry
16%
c-reactive protein
16%
cortisol
16%
design
16%
dexamethasone
100%
drugs
16%
energy
16%
genes
33%
glucocorticoids
83%
glucose
16%
humans
100%
induction
16%
inflammation
33%
insulin
16%
levels
16%
males
16%
metabolism
16%
mineralocorticoids
16%
modulation
16%
muscles
100%
plasma
33%
proteins
16%
receptors
16%
regulations
16%
sensitivity
16%
side effects
33%
tissues
100%
Immunology and Microbiology
Acute Phase Protein
16%
Adipose Tissue
100%
Blood Plasma
33%
C-Reactive Protein
16%
Dexamethasone
100%
Energy Metabolism
16%
Gene Expression Assay
16%
Glucocorticoid
83%
Hydrocortisone Urine Level
16%
Immunity
16%
Inflammation Response
16%
Insulin Sensitivity
16%
Muscle Tissue
100%
Serum Amyloid A
16%
Skeletal Muscle
100%
Target Tissue
16%
Upregulation
33%
Biochemistry, Genetics and Molecular Biology
Acute Phase Protein
16%
Biochemistry
16%
Blood Plasma
33%
C-Reactive Protein
16%
Dexamethasone
100%
Energy Metabolism
16%
Gene Expression Profiling
16%
Genomics
16%
Glucocorticoid
83%
Hydrocortisone Urine Level
16%
Immunity
16%
Insulin Sensitivity
16%
Mineralocorticoid Receptor
16%
Serum Amyloid A
16%
Skeletal Muscle
100%
Target Tissue
16%
Upregulation
33%